Bpifrance

YesWeHack is a prominent Bug Bounty and Vulnerability Management Platform founded in 2015. The company connects organizations worldwide with tens of thousands of ethical hackers who identify vulnerabilities in various digital assets, including websites and mobile applications. YesWeHack's offerings encompass a range of cybersecurity solutions, such as Bug Bounty programs, Vulnerability Disclosure Policies (VDP), Pentest Management, and Attack Surface Management platforms. Its client base includes notable organizations like ZTE, Tencent, Swiss Post, Orange France, and the French Ministry of Armed Forces. By employing ethical hackers to test for vulnerabilities, YesWeHack enables companies to enhance their security measures and effectively mitigate potential network breaches.

We created a revolutionary SaaS platform for human behavior analysis: AI x Psychology to understand human behavior in real time. Use cases: Marketing, Education, eMeetings, Healthcare, Automotive, Retail, Sport. See our partnership with Renault and STMicroelectronics : https://stern.consulting/sterntech-h1stvision.mp4

We created a revolutionary SaaS platform for human behavior analysis: AI x Psychology to understand human behavior in real time. Use cases: Marketing, Education, eMeetings, Healthcare, Automotive, Retail, Sport. See our partnership with Renault and STMicroelectronics : https://stern.consulting/sterntech-h1stvision.mp4

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Multiwave Technologies develops breakthrough magnetic resonance imaging and positron emission tomography devices, including metamaterial MRI antennas designed by its French unit. The company aims to improve MRI image quality and support clinical decision making, including portable MRI capabilities and sensor-based performance analysis. Founded in 2015 in Switzerland, it is headquartered in Geneva and conducts research and development in France, reflecting an international footprint. The business is recognized for its metamaterial MRI antenna design and positions itself as a deep science imaging innovator in neurology and other medical imaging applications.

Multiwave Technologies develops breakthrough magnetic resonance imaging and positron emission tomography devices, including metamaterial MRI antennas designed by its French unit. The company aims to improve MRI image quality and support clinical decision making, including portable MRI capabilities and sensor-based performance analysis. Founded in 2015 in Switzerland, it is headquartered in Geneva and conducts research and development in France, reflecting an international footprint. The business is recognized for its metamaterial MRI antenna design and positions itself as a deep science imaging innovator in neurology and other medical imaging applications.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

The Agent is a company that transforms the digital distribution landscape for fashion brands. It operates a platform that links numerous European designer brands with e-retailers across 30 countries, including the USA, Australia, the UK, Germany, Spain, Switzerland, Sweden, Russia, and regions in Eastern Europe, the Middle East, and Africa. By facilitating these connections, The Agent enables fashion brands to reach a broader audience and enhances the online shopping experience for consumers seeking diverse designer offerings.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Recommerce Group specializes in the trade-in, refurbishment, and remarketing of second-hand smartphones across Europe. Founded in 2009 and headquartered in Paris, France, the company employs advanced proprietary technologies to give a second life to mobile devices, offering a wide array of premium quality products under its own brand. Recommerce Group provides comprehensive solutions that include buyback services, real-time market pricing, and leasing programs, facilitating affordable access to refurbished electronics. The company serves a diverse clientele, including mobile network operators, distributors, e-tailers, and manufacturers, through both online and physical distribution channels in France, Switzerland, Spain, and beyond. Additionally, Recommerce Group offers marketing and logistical support, as well as customer services, ensuring a seamless experience for its partners and customers alike.